Study Assessing Safety and Efficacy of Combination of BL-8040 and Pembrolizumab in Metastatic Pancreatic Cancer Patients

Brief summary public domain (ClinicalTrials.gov)

This study will assess the efficacy and safety of BL-8040 in combination with pembrolizumab (Keytruda®) and BL-8040/ Pembrolizumab in combination with liposomal irinotecan (Onivyde®)/5-fluorouracil/leucovorin (5-FU/LV) in subjects with metastatic pancreatic adenocarcinoma.

Detailed description public domain (ClinicalTrials.gov)

This will be an open-label, two-cohort, phase IIa study in subjects with metastatic pancreatic adenocarcinoma. The study will be comprised of 2 cohorts,. Each includes approximately 40 subjects with unresectable metastatic pancreatic adenocarcinoma. Cohorts will be conducted sequentially (one after the other). Each cohort study consists of two periods: * Monotherapy period: One week, with BL-8040 administered daily on days 1-5. * Combination therapy: Cohort 1: Three-week cycles of a combination of BL-8040 administered three times a week (TIW) and pembrolizumab administered once every three weeks. Cohort 2: Onivyde®/5-FU/LV every 2 weeks, pembrolizumab once every 3 weeks and BL-8040 twice a week. Cohort 1: Subjects with metastatic pancreatic adenocarcinoma will be enrolled and receive BL-8040 monotherapy for five days followed by a combination treatment of BL-8040 and pembrolizumab. During the monotherapy period, eligible subjects will receive daily subcutaneous (SC) injections of BL-8040 (1.25 mg/kg) on Days 1 - 5. From Day 8, subjects will begin a combination period consisting of treatment with SC BL-8040 TIW and pembrolizumab once every three weeks. The combination therapy will continue for up to 35 cycles of pembrolizumab approximately two years), or until progression, clinical deterioration or Early Termination, whichever comes first. Cohort 2: Subjects with metastatic pancreatic adenocarcinoma that have progressed following first-line treatment with gemcitabine-based chemotherapy will be enrolled and receive BL-8040 monotherapy for five days followed by a combination treatment of BL-8040, pembrolizumab and chemotherapy. During the monotherapy period, eligible subjects will receive daily SC injections of BL-8040 on Days 1 - 5. From Day 8, subjects will begin a combination period consisting of: * IV Onivyde® followed by IV leucovorin (LV), followed by IV fluorouracil (5-FU), every 2 weeks. * Pembrolizumab every three weeks. * BL-8040 twice a week The combination therapy will continue for up to 35 treatments (approximately two years), or until progression, clinical deterioration or Early Termination, whichever comes first.

Posted results (ClinicalTrials.gov registry) · primary outcome public domain (ClinicalTrials.gov)

Objective Response Rate (ORR) Assessed by Imaging According to RECIST 1.1 Criteria [Change in response between screening, end of monotherapy (Day 5), end of cycle 2 (Day 28) and approximately every 63 days until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 24 months.]. Count Of Participants, Participants. Cohort 1: BL-8040 + Pembrolizumab (n=30): 1; Cohort 2: BL-8040 + Pembrolizumab + Chemotherapy (n=39): 8.

Posted results (ClinicalTrials.gov registry) · secondary outcome public domain (ClinicalTrials.gov)

Overall Survival [Through study completion, an average of 2 years for cohort of the study, and follow-up until date of death up to 100 weeks.]. Median, months (95% Confidence Interval). Cohort 1: BL-8040 + Pembrolizumab (n=37): 3.3 (2.8 to 7.5); Cohort 2: BL-8040 + Pembrolizumab + Chemotherapy (n=43): 6.6 (4.5 to 8.7).

Posted results (ClinicalTrials.gov registry) · secondary outcome public domain (ClinicalTrials.gov)

Progression-free Survival (PFS) by Imaging (RECIST 1.1) [Through study completion, an average of 2 years]. Median, Months (95% Confidence Interval). Cohort 1: BL-8040 + Pembrolizumab (n=37): 1.5 (1.5 to 1.8); Cohort 2: BL-8040 + Pembrolizumab + Chemotherapy (n=43): 3.8 (1.6 to 5.1).

Posted results (ClinicalTrials.gov registry) · secondary outcome public domain (ClinicalTrials.gov)

Disease Control (DC) [Through study completion, an average of 2 years]. Count Of Participants, Participants. Cohort 1: BL-8040 + Pembrolizumab (n=30): 10; Cohort 2: BL-8040 + Pembrolizumab + Chemotherapy (n=39): 25.